ACCESS Newswire

Enzolytics, Inc.

20.7.2021 13:32:08 CEST | ACCESS Newswire | Press release

Share
Enzolytics Announces the Signing of a Letter of Intent with Creative Biolabs, Inc. for Licensing and Commercialization of anti-HTLV-1 Monoclonal Antibodies

COLLEGE STATION, TX / ACCESSWIRE / July 20, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) ("Enzolytics" and the 'Company') announces the signing of a Letter of Intent (LOI) with Creative Biolabs ("Creative") (https://www.creative-biolabs.com) to complete the joint production and commercialization of HTLV-1 monoclonal antibodies by combining the technologies of the companies. There are no effective vaccines against HTLV-1 and no antiviral drugs available for treating infections caused by the virus.

The technologies of Enzolytics and Creative will be combined to achieve the objective of production and commercialization of HTLV-1 monoclonal antibodies in the following way.

Through the application of Enzolytics' proprietary Artificial Intelligence (AI) methodology, the Company has identified conserved immutable target sites on the HTLV-1 virus. The Company will produce targeted anti-HTLV-1 monoclonal antibodies (mAbs) in its lab at Texas A&M University's Institute for Preclinical Studies using the Company's proprietary technology for producing fully human monoclonal antibodies.

Pursuant to the LOI, Creative will:

  1. test the efficacy and neutralizing capability of the anti-HTLV-1 mAbs produced by Enzolytics,
  2. mass-produce the mAbs for purposes of marketing and distribution, and
  3. promote and market the HTLV-1 mAbs for uses agreed to by the Parties.

Enzolytics recognizes Creative as a significant partner in this effort as Creative is a life-science company that produces and supplies biotech products and services for early drug discovery and development, including various phage display libraries such as pre-made libraries, phage display services, antibody sequencing and antibody humanization.

Under the LOI, Creative would bear the cost of production and sale of the anti-HTLV-1 mAbs manufactured. From such sales, Creative would share with Enzolytics a percentage of net profit from sales of the anti-HTLV-1 mAbs made through Creative's channels of distribution. In the event Enzolytics chooses to commercialize the HTLV-1 mAbs, Enzolytics would share with Creative a percentage of the net profit or return generated from such sales.

Adult T-cell leukemia (ATL) and HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) are several diseases associated with HTLV-1. More than 20 million people worldwide are infected with the virus. Up to 10% will develop the debilitating and sometimes deadly disease. HTLV-1 causes adult T-cell leukemia/lymphoma (ATL), HTLV-associated myelopathy (HAM), spastic paraparesis, and other rare illnesses. Signs and symptoms of HTLV-1 infection include motor and sensory changes in the extremities, inflammation in the spinal cord, a spastic gait in combination with weakness of the lower limbs, cognitive impairment, bladder dysfunction and bladder cancer. HTLV-1 is similar to the human immunodeficiency virus (HIV), is transmitted through sexual contact, from mother to child via breastfeeding and through exposure to contaminated blood.

HTLV-1 requires cell-to-cell contact for efficient transmission. The virus utilizes Envelope (Env) glycoprotein-mediated cell binding and entry. Using Enzolytics' proprietary AI methodology, multiple conserved sites have been identified in the outer envelope of the HTLV-1 virus. Enzolytics continues to harness the power of artificial intelligence, in conjunction with the Company's proprietary fully human monoclonal antibody methodology, to create universal, durable, broadly neutralizing monoclonal antibodies against multiple viruses, now to include monoclonal antibodies against HTLV-1.

Charles Cotropia, CEO of Enzolytics, said: 'We now have a comprehensive platform for producing multiple targeted monoclonal antibodies against numerous infectious diseases. This platform includes our ability to identify multiple conserved and immutable sites on viruses to produce fully human monoclonal antibodies targeting those sites. This approach opens the door to new and durable therapies that can be used to treat innumerable human infectious diseases. We are now discussing licensing, commercialization, and distribution of these monoclonal antibodies with various pharmaceutical partners to expedite the development. We have completed the process of identifying conserved sites for HIV, the Coronavirus (SARS-CoV-2), HTLV-1, Influenza-A and Influenza-B. In addition, we have an ongoing AI analysis to identify conserved, immutable sites for HINI Influenza, HINI, H10N3, Herpes zoster, Varicella zoster, Herpes HSV 1/2, Koala Retrovirus, Feline Leukemia virus, Elephant Endotheliotropic Herpesvirus, and Feline Immunodeficiency virus.'

About Enzolytics, Inc.

Enzolytics, Inc. is a drug development company committed to commercializing its multiple proprietary therapeutics to treat debilitating infectious diseases. The Company's patented ITV-1 therapeutic suspension of Inactivated Pepsin Fraction (IPF), which studies have shown effectively treats HIV/AIDS. IPF is the active component of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has also been shown to modulate the immune system.

Additionally, the Company has proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases, including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. In addition, its proprietary methodology for producing fully human monoclonal antibodies is currently employed to produce monoclonal antibody therapeutics to treat other infectious diseases, including the Coronavirus (SARS-CoV-2).

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Enzolytics, Inc. from time to time in its periodic reports filed with the SEC. ITV-1 is not approved by the U.S. Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world.

While Enzolytics, Inc. believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of the Company to establish the efficacy of ITV-1 or its other therapeutics in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of its therapeutics in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate.

Such forward-looking statements are based on current expectations. They involve inherent risks and uncertainties, including factors that could delay, divert or change any of the statements made, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release. The Company expressly disclaims any intention or obligation to update the forward-looking statements or update the reasons why actual results could differ from those projected in the forward-looking statements.

I.R. contact

TEN Associates, LLC
Tom Nelson, CEO
(480) 326-8577
Investor Relations Contact

Company Contact

Enzolytics, Inc.
2000 North Central Expressway
Plano, TX 75074

and

Research Center
Enzolytics, Inc.
Texas A&M University
Institute for Preclinical Studies
College Station, TX 77843-44

SOURCE: Enzolytics, Inc.



View source version on accesswire.com:
https://www.accesswire.com/656086/Enzolytics-Announces-the-Signing-of-a-Letter-of-Intent-with-Creative-Biolabs-Inc-for-Licensing-and-Commercialization-of-anti-HTLV-1-Monoclonal-Antibodies

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Tosca's 2026 Sustainability Report Makes the Case for Packaging as Critical Supply Chain Infrastructure20.11.2026 08:00:00 CET | Press release

BRUSSELS, BE / ACCESS Newswire / November 20, 2026 / Tosca, a global leader in reusable packaging and pooling solutions, has released its 2026 Sustainability Report, calling for a shift in how businesses evaluate transport packaging: from a purchased commodity to a strategic component of supply chain infrastructure. As food supply chains become more automated and face mounting cost and regulatory pressures, packaging decisions increasingly influence operational performance. The report examines how reusable packaging can reduce food loss, labor requirements and transportation inefficiencies while documenting Tosca's progress toward its global sustainability goals. "Companies invest significant resources in optimizing equipment, labor and transportation, yet packaging is still too often evaluated primarily on unit price," said Eric Frank, CEO of Tosca. "That approach overlooks its role in keeping automated lines running, protecting products and moving goods efficiently. Packaging is an o

Global Scams Remain Widespread: Nearly Two in Three Adults Worldwide Report Scam Encounters, 9% Lost Money19.11.2026 18:01:00 CET | Press release

THE HAGUE, NL / ACCESS Newswire / November 19, 2026 / The Global Anti-Scam Alliance (GASA), in collaboration with Outseer, today released the Global State of Scams 2026 report. Based on a survey of 58,900 adults across 42 markets, the report examines how often people encounter scams, how they respond, and the financial and emotional impact on those affected. In the past 12 months, 64% of adults worldwide encountered a scam and 9% lost money. Shopping, investment, and unexpected money scams were among the types people most often interacted with. In Africa, 21% of adults lost money to a scam, more than double the global rate. The research also highlights the emotional toll of scams. Among people who lost money, 69% reported a significant or moderate impact on their mental wellbeing, 20% reported increased tension at home, and 16% said they could not pay for essentials such as rent or groceries. Among those who did not report the scam to an organization, the most common reason was uncerta

After 20 Years of Modernizing Other Companies' Software, Polcode Turns the Lens on Itself19.11.2026 15:00:00 CET | Press release

WARSAW, PL / ACCESS Newswire / November 19, 2026 / Polcode, a software development company that has helped businesses across North America and Europe modernize their technology since 2006, launched its new website at polcode.com this week. Timed to the company's 20th anniversary, the launch is more than a redesign. It applies the same modernization approach Polcode brings to client systems every day to its own brand. For 20 years, Polcode has been the team businesses call when software stops keeping up with the business: aging platforms, tangled integrations, and tools nobody dares touch. So when it came time to rebuild its own website, the question was fair. Would a company that modernizes for others hold itself to the same standard? The new site is Polcode's answer, serving as both a showcase of what the company does and an example of it. We spend a lot of time helping businesses move beyond systems that no longer reflect where they're headed. At some point, we had to ask ourselves t

Karbon-X (OTCQB:KARX) Enters California's Multi-Billion-Dollar Compliance Carbon Market Following CITSS Approval19.11.2026 13:45:00 CET | Press release

CALGARY, AB / ACCESS Newswire / November 19, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a global carbon and environmental markets company, today announced that it has completed registration under the Compliance Instrument Tracking System Service (CITSS), enabling the Company to participate directly in California's regulated compliance carbon market. This milestone elevates Karbon-X's North American trading infrastructure, enabling the Company to directly source, hold, and transact compliance allowances and eligible offset credits, positioning the Company to capture trading margins and recurring commercial opportunities from California's ongoing compliance demand. Unlike voluntary carbon markets, California's Cap-and-Invest Program is backed by state regulation requiring covered entities to surrender eligible compliance instruments against their emissions obligations, creating recurring regulatory demand for allowances and eligible offset credits. California's pro

Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor18.11.2026 15:30:00 CET | Press release

DETROIT, MI / ACCESS Newswire / November 18, 2026 / Leggett Dynamics has won a 2026 Automotive News PACE Pilot Award for its Smart Brushless Motor. This next-generation motion system simplifies vehicle integration, improves performance and supports the industry's transition to software-defined vehicles (SDVs). Leggett Dynamics' Smart Brushless Motor streamlines motion-control architecture by operating with or without a seat-level electronic control unit (ECU). The system enables direct communication between the vehicle-level ECU and individual actuators, supporting more centralized and zonal vehicle architectures while reducing packaging size, weight and wiring complexity. It also improves noise, vibration and harshness (NVH), durability, and electromagnetic compatibility (EMC). "As automakers transition to software-defined vehicles, they are looking for solutions that reduce complexity without compromising performance," said Julien Rea, VP of Global Innovation and Engineering at Legge

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye